Company Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
958.4 INR -0.42% Intraday chart for Glenmark Pharmaceuticals Limited +1.82% +12.24%

Business Summary

Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

Number of employees: 15,556

Sales per Business

INR in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
123,049 100.0 % 129,901 100.0 % +5.57%

Sales per region

INR in Million2022Weight2023Weight Delta
India
34.4 %
43,809 35.6 % 44,675 34.4 % +1.98%
North America
25.0 %
32,035 26.0 % 32,484 25.0 % +1.40%
Europe
17.7 %
20,047 16.3 % 23,047 17.7 % +14.97%
Rest of the World
17.3 %
21,031 17.1 % 22,414 17.3 % +6.58%
Latin America
5.6 %
6,127 5.0 % 7,281 5.6 % +18.83%

Managers

Managers TitleAgeSince
Founder - -
Chief Executive Officer 54 98-10-11
President - -
President - 22-05-31
Director of Finance/CFO 59 17-11-15
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Compliance Officer - 17-02-01
Director/Board Member 65 82-12-31
Director/Board Member 56 99-10-05

Members of the board

Members of the board TitleAgeSince
Director/Board Member 59 20-08-13
Director/Board Member 51 05-04-25
Director/Board Member 56 99-10-05
Chief Executive Officer 54 98-10-11
Director/Board Member 65 82-12-31
Director/Board Member 86 09-08-13
Director/Board Member 83 09-08-13
Director/Board Member - 12-01-29
Director/Board Member 48 19-03-31
Director of Finance/CFO 59 17-11-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 282,188,156 138,368,096 ( 49.03 %) 0 49.03 %

Shareholders

NameEquities%Valuation
128,241,936 45.45 % 1 432 M ₹
HSBC Global Asset Management (Hong Kong) Ltd.
3.606 %
10,175,644 3.606 % 114 M ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt)
2.564 %
7,236,081 2.564 % 81 M ₹
7,200,000 2.552 % 80 M ₹
Aditya Birla Sun Life Amc Ltd. (Investment Management)
2.429 %
6,852,742 2.429 % 77 M ₹
NTAsset (Thailand) Co., Ltd.
2.312 %
6,525,000 2.312 % 73 M ₹
Life Insurance Corporation of India (Investment Portfolio)
2.224 %
6,274,132 2.224 % 70 M ₹
Ellipsis Partners LLC
1.683 %
4,750,000 1.683 % 53 M ₹
UTI Asset Management Co. Ltd. (Investment Management)
0.4882 %
1,377,479 0.4882 % 15 M ₹
Aditya Birla Sun Life Insurance Co. Ltd.
0.4753 %
1,341,173 0.4753 % 15 M ₹

Holdings

NameEquities%Valuation
9,609,571 7.84% 100,677,938 $

Company contact information

Glenmark Pharmaceuticals Ltd.

Glenmark House Off Western Express Highway

400099, Mumbai

+91 22 4018 9999

http://www.glenmarkpharma.com
address Glenmark Pharmaceuticals Limited(GLENMARK)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Pharmaceuticals: Major

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
962.4 INR
Average target price
923 INR
Spread / Average Target
-4.10%
Consensus

Quarterly revenue - Rate of surprise